met proto-oncogene (hepatocyte growth factor receptor)
met proto-oncogene
Scatter factor receptor
SF receptor
Met proto-oncogene tyrosine kinase
HGF/SF receptor
Background Information
The proto-oncogene Met (c-Met, HGF/SF Receptor, HGFR) is a receptor tyrosine kinase that is activated upon Hepatocyte Growth Factor (HGF) binding. This stimulates the autophosphorylation on Tyr1234/Tyr1235 which leads to pleiotropic downstream signaling events in epithelial cells that stimulate multiple cellular processes including cell proliferation, growth, differentiation, cell migration/ invasion, and tumorigenesis. These effects are mediated by SH2 domain-containing proteins that bind to the C-terminal tail of c-Met. Chronic stimulation of Met on cancer cells is thought to play a role in metastasis and dysregulation of c-Met activity is directly associated with oncogenesis, making it an important cancer target.
Product Information
Format
Purified
Presentation
Purified mouse monoclonal in 0.1M Tris-Glycine (pH7.4), 150mM NaCl with 0.05% NaN3.
Applications
Application
Detect Met (extracellular) using this Anti-Met (extracellular) Antibody, clone 4F8.2 validated for use in IH(P) & WB.
Key Applications
Immunohistochemistry (Paraffin)
Western Blotting
Application Notes
Western Blot Analysis:
This lot detected Met at 1:1,000 dilution in HEK293 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Immunohistochemistry Analysis :
Biological Information
Immunogen
GST-fusion protein corresponding to amino acids 80-434 of human Met.
Epitope
Extracelluar domain (N-term)
Clone
4F8.2
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq].
FUNCTION:Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity.
Catalytic activity ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
SUBUNIT:Heterodimer formed of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1 and GRB2. Interacts with SPSB1, SPSB2 and SPSB4 By similarity. Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction.
LOCATION:Single-pass type I membrane protein.
DOMAIN:The kinase domain is involved in SPSB1 binding.
DISEASE: Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of hereditary papillary renal carcinoma (HPRC) [MIM:605074]; also known as papillary renal cell carcinoma 2 (RCCP2). HPRC is a form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance.
Genetic variations in MET may be associated with susceptibility to autism type 1B (AUTS1B) [MIM:608636]. Autism is a neurodevelopmental disorder characterized by disturbance in language, perception and socialization. The disorder is classically defined by a triad of limited or absent verbal communication, a lack of reciprocal social interaction or responsiveness, and restricted, stereotypical, and ritualized patterns of interests and behavior.
SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
Product Usage Statements
Quality Assurance
Routinely evaluated by Western Blot.
Western Blot Analysis:
This lot detected Met at 1:1,000 dilution in HEK293 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at 2-8°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
Packaging Information
Material Size
100 µg
原厂资料：
Key Spec Table
Species Reactivity
Key Applications
Host
Format
Antibody Type
H
IH(P), WB
M
Purified
Monoclonal Antibody
Description
Catalogue Number
05-1049
Replaces
05-237
Description
Anti-Met (extracellular) Antibody, clone 4F8.2
Alternate Names
HGF receptor
oncogene MET
met proto-oncogene (hepatocyte growth factor receptor)
met proto-oncogene
Scatter factor receptor
SF receptor
Met proto-oncogene tyrosine kinase
HGF/SF receptor
Background Information
The proto-oncogene Met (c-Met, HGF/SF Receptor, HGFR) is a receptor tyrosine kinase that is activated upon Hepatocyte Growth Factor (HGF) binding. This stimulates the autophosphorylation on Tyr1234/Tyr1235 which leads to pleiotropic downstream signaling events in epithelial cells that stimulate multiple cellular processes including cell proliferation, growth, differentiation, cell migration/ invasion, and tumorigenesis. These effects are mediated by SH2 domain-containing proteins that bind to the C-terminal tail of c-Met. Chronic stimulation of Met on cancer cells is thought to play a role in metastasis and dysregulation of c-Met activity is directly associated with oncogenesis, making it an important cancer target.
Product Information
Format
Purified
Presentation
Purified mouse monoclonal in 0.1M Tris-Glycine (pH7.4), 150mM NaCl with 0.05% NaN3.
Applications
Application
Detect Met (extracellular) using this Anti-Met (extracellular) Antibody, clone 4F8.2 validated for use in IH(P) & WB.
Key Applications
Immunohistochemistry (Paraffin)
Western Blotting
Application Notes
Western Blot Analysis:
This lot detected Met at 1:1,000 dilution in HEK293 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Immunohistochemistry Analysis :
Biological Information
Immunogen
GST-fusion protein corresponding to amino acids 80-434 of human Met.
Epitope
Extracelluar domain (N-term)
Clone
4F8.2
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq].
FUNCTION:Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity.
Catalytic activity ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
SUBUNIT:Heterodimer formed of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1 and GRB2. Interacts with SPSB1, SPSB2 and SPSB4 By similarity. Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction.
LOCATION:Single-pass type I membrane protein.
DOMAIN:The kinase domain is involved in SPSB1 binding.
DISEASE: Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of hereditary papillary renal carcinoma (HPRC) [MIM:605074]; also known as papillary renal cell carcinoma 2 (RCCP2). HPRC is a form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance.
Genetic variations in MET may be associated with susceptibility to autism type 1B (AUTS1B) [MIM:608636]. Autism is a neurodevelopmental disorder characterized by disturbance in language, perception and socialization. The disorder is classically defined by a triad of limited or absent verbal communication, a lack of reciprocal social interaction or responsiveness, and restricted, stereotypical, and ritualized patterns of interests and behavior.
SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
Product Usage Statements
Quality Assurance
Routinely evaluated by Western Blot.
Western Blot Analysis:
This lot detected Met at 1:1,000 dilution in HEK293 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at 2-8°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
